How have POAI shares performed in 2024?

Predictive Oncology's stock was trading at $3.29 on January 1st, 2024. Since then, POAI stock has decreased by 54.1% and is now trading at $1.51. View the best growth stocks for 2024 here .

Are investors shorting Predictive Oncology?

Predictive Oncology saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 25,500 shares, an increase of 129.7% from the March 15th total of 11,100 shares. Based on an average daily volume of 23,600 shares, the days-to-cover ratio is presently 1.1 days. Approximately 0.7% of the shares of the stock are short sold. View Predictive Oncology's Short Interest .

When is Predictive Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our POAI earnings forecast .

How were Predictive Oncology's earnings last quarter?

Predictive Oncology Inc. (NASDAQ:POAI) posted its earnings results on Wednesday, August, 11th. The medical instruments supplier reported ($1.00) earnings per share for the quarter, beating the consensus estimate of ($1.60) by $0.60. The medical instruments supplier had revenue of $0.35 million for the quarter, compared to the consensus estimate of $0.80 million. Predictive Oncology had a negative trailing twelve-month return on equity of 104.21% and a negative net margin of 785.62%.

When did Predictive Oncology's stock split?

Shares of Predictive Oncology reverse split on Monday, April 24th 2023. The 1-20 reverse split was announced on Monday, April 24th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Predictive Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Predictive Oncology investors own include NVIDIA (NVDA) , OPKO Health (OPK) , Enphase Energy (ENPH) , Inovio Pharmaceuticals (INO) , Overstock.com (OSTK) , Riot Platforms (RIOT) , AcelRx Pharmaceuticals (ACRX) , Boeing (BA) , QUALCOMM (QCOM) and Sorrento Therapeutics (SRNE) .

How do I buy shares of Predictive Oncology?

Shares of POAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:POAI

Predictive Oncology (POAI) Stock Price, News & Analysis

→ Forget Nvidia, buy this A.I. Stock Now (From InvestorPlace) (Ad)

Free POAI Stock Alerts

$1.51

-0.25 (-14.20%)

(As of 04/15/2024 ET)

Compare

Today's Range: $1.46
▼
$1.79
50-Day Range: $1.51
▼
$3.72
52-Week Range: $1.46
▼
$7.12

Volume: 41,711 shs
Average Volume: 26,675 shs
Market Capitalization: $6.13 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Predictive Oncology alerts:

Ad InvestorPlace

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

Click here to see the details.

About Predictive Oncology Stock (NASDAQ:POAI)

Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.

POAI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

POAI Stock News Headlines

April 11, 2024 | finance.yahoo.com

Predictive Maintenance Market Worth $47.8 billion by 2029, Growing At a CAGR of 35.1% Report by MarketsandMarkets™

April 2, 2024 | finance.yahoo.com

Predictive Oncology Inc. (NASDAQ:POAI) Q4 2023 Earnings Call Transcript

April 16, 2024 | Porter & Company (Ad)

The #1 Investment of the Decade…

Sam Altman, the CEO of OpenAI, has invested $375 million into a breakthrough technology, that legendary financial analyst Porter Stansberry believes… …could be the number-one investment of the decade.

April 2, 2024 | finance.yahoo.com

Q4 2023 Predictive Oncology Inc Earnings Call

March 31, 2024 | finance.yahoo.com

Predictive Oncology Full Year 2023 Earnings: US$3.48 loss per share (vs US$7.05 loss in FY 2022)

March 29, 2024 | finanznachrichten.de

Predictive Maintenance Market worth $47.8 billion by 2029 - Exclusive Report by MarketsandMarkets

March 29, 2024 | finance.yahoo.com

Predictive Maintenance Market worth $47.8 billion by 2029 - Exclusive Report by MarketsandMarkets™

March 29, 2024 | msn.com

Predictive Oncology GAAP EPS of -$3.48, revenue of $1.78M

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

March 29, 2024 | investorplace.com

POAI Stock Earnings: Predictive Oncology Reported Results for Q4 2023

March 28, 2024 | globenewswire.com

Predictive Oncology Reports Year End 2023 Financial Results and Provides Business Update

March 13, 2024 | finance.yahoo.com

WorldQuant Predictive Appoints Amir Husain as Chairman of the Board

February 24, 2024 | msn.com

Predictive tests: How accurate?

February 21, 2024 | finance.yahoo.com

Predictive Oncology to Participate in Upcoming Investor Conferences

February 21, 2024 | globenewswire.com

Predictive Oncology to Participate in Upcoming Investor Conferences

February 9, 2024 | msn.com

Predictive Oncology Announces Chief Business Officer Transition

February 3, 2024 | finance.yahoo.com

Global Predictive Analytics Market: Forecasts Significant Growth Through 2030

February 1, 2024 | finance.yahoo.com

Point Predictive Fortifies Auto Dealership Business Line, Inks Deals Bringing on Hundreds of Rooftops

February 1, 2024 | es-us.finanzas.yahoo.com

Insights-as-a-Service Market Forecast Shows Strong Growth with Predictive Analysis Leading the Charge

January 30, 2024 | finance.yahoo.com

Global Industrial Analytics Market Forecast 2024-2030: Predictive Analytics Segment Showing Strong Upsurge through 2030

November 14, 2023 | finanznachrichten.de

Predictive Oncology Inc.: Predictive Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update

November 14, 2023 | proactiveinvestors.com

Predictive Oncology 'pleased with progress' as it delivers 3Q results

November 14, 2023 | msn.com

Predictive Oncology GAAP EPS of -$0.78, revenue of $0.72M

November 14, 2023 | finance.yahoo.com

Predictive Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update

November 10, 2023 | morningstar.com

Predictive Oncology Inc POAI

November 8, 2023 | proactiveinvestors.com

Predictive Oncology completes AI-driven cancer study with UPMC Magee-Womens Hospital

November 8, 2023 | markets.businessinsider.com

Predictive Oncology Completes AI-driven Study of Ovarian Cancer with UPMC Magee-Womens Hospital

See More Headlines

Receive POAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Predictive Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/11/2021
Today: 4/15/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical appliances & supplies
Sub-Industry: N/A
Current Symbol: NASDAQ:POAI
CUSIP: N/A
CIK: 1446159
Web: www.precisiontherapeutics.com
Phone: (651) 389-4800
Fax: N/A
Employees: 31
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($3.47)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-13,980,000.00
Net Margins: -785.62%
Pretax Margin: -785.62%
Return on Equity: -104.21%
Return on Assets: -70.49%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.55
Quick Ratio: 2.43

Sales & Book Value

Annual Sales: $1.78 million
Price / Sales: 3.44
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.04 per share
Price / Book: 0.74

Miscellaneous

Outstanding Shares: 4,060,000
Free Float: 3,923,000
Market Cap: $6.13 million
Optionable: Not Optionable
Beta: 1.29

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Raymond F. Vennare (Age 72)
CEO & Chairman
Comp: $581.58k
Mr. Joshua Blacher M.B.A. (Age 51)
Interim Chief Financial Officer
Ms. Theresa Ferguson
Senior Director of Marketing
Dr. Lawrence J. DeLucas D.Sc
O.D, Ph.D., Senior Vice President of Biologics
Dr. Arlette H. Uihlein FCAP
M.D., Senior VP of Translational Medicine & Drug Discovery and Medical Director

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

POAI Stock Analysis - Frequently Asked Questions

How have POAI shares performed in 2024?: Predictive Oncology's stock was trading at $3.29 on January 1st, 2024. Since then, POAI stock has decreased by 54.1% and is now trading at $1.51.
View the best growth stocks for 2024 here.
Are investors shorting Predictive Oncology?: Predictive Oncology saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 25,500 shares, an increase of 129.7% from the March 15th total of 11,100 shares. Based on an average daily volume of 23,600 shares, the days-to-cover ratio is presently 1.1 days. Approximately 0.7% of the shares of the stock are short sold.
View Predictive Oncology's Short Interest.
When is Predictive Oncology's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our POAI earnings forecast.
How were Predictive Oncology's earnings last quarter?: Predictive Oncology Inc. (NASDAQ:POAI) posted its earnings results on Wednesday, August, 11th. The medical instruments supplier reported ($1.00) earnings per share for the quarter, beating the consensus estimate of ($1.60) by $0.60. The medical instruments supplier had revenue of $0.35 million for the quarter, compared to the consensus estimate of $0.80 million. Predictive Oncology had a negative trailing twelve-month return on equity of 104.21% and a negative net margin of 785.62%.

When did Predictive Oncology's stock split?: Shares of Predictive Oncology reverse split on Monday, April 24th 2023. The 1-20 reverse split was announced on Monday, April 24th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of Predictive Oncology own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Predictive Oncology investors own include NVIDIA (NVDA), OPKO Health (OPK), Enphase Energy (ENPH), Inovio Pharmaceuticals (INO), Overstock.com (OSTK), Riot Platforms (RIOT), AcelRx Pharmaceuticals (ACRX), Boeing (BA), QUALCOMM (QCOM) and Sorrento Therapeutics (SRNE).
How do I buy shares of Predictive Oncology?: Shares of POAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:POAI) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial